Jasper Therapeutics, Inc. (JSPR)
Largest Insider Buys in Sector
JSPR Stock Price History Chart
JSPR Stock Performance
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning …
Insider Activity of Jasper Therapeutics, Inc.
Over the last 12 months, insiders at Jasper Therapeutics, Inc. have bought $6.99M and sold $84,534 worth of Jasper Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Jasper Therapeutics, Inc. have bought $7.86M and sold $527,595 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Carlyle Group Inc. (Former 10% Owner) — $14.76M. Velan Capital Investment Management LP (10 percent owner) — $4.53M.
The last purchase of 350,000 shares for transaction amount of $4.53M was made by Velan Capital Investment Management LP (10 percent owner) on 2024‑02‑08.
List of Insider Buy and Sell Transactions, Jasper Therapeutics, Inc.
| 2024-12-12 | Sale | Chief Operating Officer | 900 0.0065% | $22.11 | $19,899 | +5.08% | ||
| 2024-09-12 | Sale | Chief Operating Officer | 900 0.0245% | $21.23 | $19,104 | +0.40% | ||
| 2024-06-12 | Sale | Chief Operating Officer | 900 0.0279% | $24.16 | $21,740 | -13.54% | ||
| 2024-03-12 | Sale | Chief Operating Officer | 900 0.0306% | $26.44 | $23,792 | -16.00% | ||
| 2024-02-08 | 10 percent owner | 350,000 5.8207% | $12.95 | $4.53M | +25.35% | |||
| 2024-02-08 | Former 10% Owner | 190,000 3.1598% | $12.95 | $2.46M | +25.35% | |||
| 2023-11-28 | director | 10,000 0.0091% | $0.65 | $6,486 | +219.69% | |||
| 2023-11-21 | director | 10,000 0.009% | $0.64 | $6,383 | +221.76% | |||
| 2023-11-20 | director | 10,000 0.0089% | $0.63 | $6,309 | +219.97% | |||
| 2023-11-17 | director | 10,000 0.0087% | $0.60 | $5,966 | +224.56% | |||
| 2023-11-16 | director | 10,000 0.009% | $0.60 | $5,965 | +233.33% | |||
| 2023-10-13 | Sale | director | 7,965 0.007% | $0.85 | $6,777 | +122.53% | ||
| 2023-06-13 | Sale | See Remarks | 9,000 0.0098% | $1.66 | $14,915 | -20.35% | ||
| 2023-04-14 | Sale | director | 7,000 0.0081% | $1.48 | $10,360 | -8.28% | ||
| 2023-04-13 | Sale | director | 8,500 0.0093% | $1.44 | $12,240 | -11.33% | ||
| 2023-04-13 | Sale | director | 9,075 0.0102% | $1.49 | $13,524 | -11.33% | ||
| 2023-01-27 | 10 percent owner | 3.13M 3.0639% | $1.50 | $4.7M | -21.84% | |||
| 2023-01-27 | 10 percent owner | 2.67M 2.6076% | $1.50 | $4M | -21.84% | |||
| 2023-01-25 | Sale | director | 75,000 0.0869% | $1.89 | $141,750 | -25.95% | ||
| 2022-06-24 | Sale | 49,486 0.1191% | $2.05 | $101,434 | -30.77% |
Insider Historical Profitability
| Velan Capital Investment Management LP | 10 percent owner | 1188500 7.9226% | $21.99 | 1 | 0 | |
| Carlyle Group Inc. | Former 10% Owner | 1066189 7.1073% | $21.99 | 2 | 0 | <0.0001% |
| Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 8519648 56.7924% | $21.99 | 1 | 0 | <0.0001% |
| WIGGANS THOMAS G | director | 50000 0.3333% | $21.99 | 5 | 0 | +223.86% |